[On the inapplicability of certain therapeutic guidelines in practice: the example of reimbursement for hypolipidemic agents in Belgium].
International guidelines from the Task Force of European and other Societies on Coronary Prevention and national guidelines from the Belgian Lipid Club recently emphasized the potential interest of adequate management of patients with even moderate hypercholesterolaemia. However, current criteria for the reimbursement of lipid-lowering drugs in Belgium do not allow to follow these guidelines. A solution should be urgently found in order to bridge the gap and permit practitioners, after diet failure, to effectively prescribe lipid-lowering agents in patients who should benefit in priority of such a treatment. It is certainly the case in secondary prevention as well as, in high risk individuals, in primary prevention, i.e. in situations where these drugs have provided enough evidence of their efficacy with an acceptable cost-benefit ratio.
Scheen
A J
AJ
Département de Médecine, Université de Liège.
D000924:Anticholesteremic Agents / Q000191:economics* / Q000627:therapeutic use; D001530:Belgium; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D019317:Evidence-Based Medicine; D006291:Health Policy; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D019458:Insurance Coverage; D007349:Insurance, Health, Reimbursement
D000924:Anticholesteremic Agents